Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand?
Venous thromboembolism (VTE), comprising deep-vein thrombosis and pulmonary embolism, is a frequent complication in ambulatory cancer patients. Despite the high risk, routine thromboprophylaxis is not recommended because of the high number needed to treat and the risk of bleeding. Two recent trials...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/2/367 |
| _version_ | 1797761845960900608 |
|---|---|
| author | Frits I. Mulder Floris T. M. Bosch Nick van Es |
| author_facet | Frits I. Mulder Floris T. M. Bosch Nick van Es |
| author_sort | Frits I. Mulder |
| collection | DOAJ |
| description | Venous thromboembolism (VTE), comprising deep-vein thrombosis and pulmonary embolism, is a frequent complication in ambulatory cancer patients. Despite the high risk, routine thromboprophylaxis is not recommended because of the high number needed to treat and the risk of bleeding. Two recent trials demonstrated that the number needed to treat can be reduced by selecting cancer patients at high risk for VTE with prediction scores, leading the latest guidelines to suggest such an approach in clinical practice. Yet, the interpretation of these trial results and the translation of the guideline recommendations to clinical practice may be less straightforward. In this clinically-oriented review, some of the controversies are addressed by focusing on the burden of VTE in cancer patients, discussing the performance of available risk assessment scores, and summarizing the findings of recent trials. This overview can help oncologists, hematologists, and vascular medicine specialists decide about thromboprophylaxis in ambulatory cancer patients. |
| first_indexed | 2024-03-12T19:19:06Z |
| format | Article |
| id | doaj.art-752131f09f1446bcb0433332fcf2f536 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T19:19:06Z |
| publishDate | 2020-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-752131f09f1446bcb0433332fcf2f5362023-08-02T05:17:46ZengMDPI AGCancers2072-66942020-02-0112236710.3390/cancers12020367cancers12020367Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand?Frits I. Mulder0Floris T. M. Bosch1Nick van Es2Department of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The NetherlandsDepartment of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The NetherlandsDepartment of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The NetherlandsVenous thromboembolism (VTE), comprising deep-vein thrombosis and pulmonary embolism, is a frequent complication in ambulatory cancer patients. Despite the high risk, routine thromboprophylaxis is not recommended because of the high number needed to treat and the risk of bleeding. Two recent trials demonstrated that the number needed to treat can be reduced by selecting cancer patients at high risk for VTE with prediction scores, leading the latest guidelines to suggest such an approach in clinical practice. Yet, the interpretation of these trial results and the translation of the guideline recommendations to clinical practice may be less straightforward. In this clinically-oriented review, some of the controversies are addressed by focusing on the burden of VTE in cancer patients, discussing the performance of available risk assessment scores, and summarizing the findings of recent trials. This overview can help oncologists, hematologists, and vascular medicine specialists decide about thromboprophylaxis in ambulatory cancer patients.https://www.mdpi.com/2072-6694/12/2/367venous thromboembolismcancer-associated venous thromboembolismthrombosispulmonary embolismneoplasmsanticoagulantsdirect oral anticoagulantscoumarinslow molecular weight heparins |
| spellingShingle | Frits I. Mulder Floris T. M. Bosch Nick van Es Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand? Cancers venous thromboembolism cancer-associated venous thromboembolism thrombosis pulmonary embolism neoplasms anticoagulants direct oral anticoagulants coumarins low molecular weight heparins |
| title | Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand? |
| title_full | Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand? |
| title_fullStr | Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand? |
| title_full_unstemmed | Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand? |
| title_short | Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand? |
| title_sort | primary thromboprophylaxis in ambulatory cancer patients where do we stand |
| topic | venous thromboembolism cancer-associated venous thromboembolism thrombosis pulmonary embolism neoplasms anticoagulants direct oral anticoagulants coumarins low molecular weight heparins |
| url | https://www.mdpi.com/2072-6694/12/2/367 |
| work_keys_str_mv | AT fritsimulder primarythromboprophylaxisinambulatorycancerpatientswheredowestand AT floristmbosch primarythromboprophylaxisinambulatorycancerpatientswheredowestand AT nickvanes primarythromboprophylaxisinambulatorycancerpatientswheredowestand |